Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

Sharplink, Inc. logo
Sharplink, Inc. SBET
$1.07—
Sharplink, Inc. logo
Sharplink, Inc. SBET
$2.49+17.5%
WSFS Financial logo
WSFS FinancialWSFS
$0.00-100%
KEE
Keel Infrastructure Corp. Common StockKEEL
$0.93-21.8%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$47.13+56.3%
Phillips 66 logo
Phillips 66PSX
$90.11+0.9%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Pacira BioSciences, Inc. (PCRX) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $40.25 in Q1 2026.
How has Pacira BioSciences, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Pacira BioSciences, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price decreased by 4.7% year-over-year, from $42.23 to $40.25.
What is the long-term trend for Pacira BioSciences, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a -2.4% compound annual growth rate (CAGR), from $45.98 to $40.65.